CirCode Biomed secured FDA clearance to begin a first‑in‑human clinical trial in the U.S. testing a circular RNA therapeutic, marking a significant milestone for an emergent modality. The company, which has been developing circular RNA platforms, will now evaluate safety and early signals of activity under an Investigational New Drug application. The clearance positions CirCode among a small group of companies translating circular RNA from preclinical validation to clinical testing, and it will draw attention from investors and partners focused on next‑generation nucleic acid medicines. Trial outcomes will influence broader industry interest in circular RNA as an alternative to linear mRNA approaches.